[go: up one dir, main page]

AU4754397A - Bispecific molecules directed to tumor associated glycoprotein-72 and fc receptor - Google Patents

Bispecific molecules directed to tumor associated glycoprotein-72 and fc receptor

Info

Publication number
AU4754397A
AU4754397A AU47543/97A AU4754397A AU4754397A AU 4754397 A AU4754397 A AU 4754397A AU 47543/97 A AU47543/97 A AU 47543/97A AU 4754397 A AU4754397 A AU 4754397A AU 4754397 A AU4754397 A AU 4754397A
Authority
AU
Australia
Prior art keywords
receptor
tumor associated
bispecific molecules
associated glycoprotein
molecules directed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU47543/97A
Inventor
Yashwant M. Deo
Tibor Keler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
Medarex LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex LLC filed Critical Medarex LLC
Publication of AU4754397A publication Critical patent/AU4754397A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU47543/97A 1997-10-15 1997-10-15 Bispecific molecules directed to tumor associated glycoprotein-72 and fc receptor Abandoned AU4754397A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1997/018428 WO1999019362A1 (en) 1997-10-15 1997-10-15 BISPECIFIC MOLECULES DIRECTED TO TUMOR ASSOCIATED GLYCOPROTEIN-72 AND Fc RECEPTOR

Publications (1)

Publication Number Publication Date
AU4754397A true AU4754397A (en) 1999-05-03

Family

ID=22261860

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47543/97A Abandoned AU4754397A (en) 1997-10-15 1997-10-15 Bispecific molecules directed to tumor associated glycoprotein-72 and fc receptor

Country Status (2)

Country Link
AU (1) AU4754397A (en)
WO (1) WO1999019362A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530627B2 (en) 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
ES2381617T5 (en) 2002-08-14 2016-02-24 Macrogenics, Inc. Specific antibodies against FcgammaRIIB and its procedures for use
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
MXPA06012601A (en) 2004-05-10 2007-05-10 Macrogenics Inc HUMANIZED FcgammaRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF.
JP5330826B2 (en) 2005-04-28 2013-10-30 ジェネンコー・インターナショナル・インク TAB molecule
EP2021029B1 (en) 2006-05-26 2014-06-11 MacroGenics, Inc. Humanized fc gamma riib-specific antibodies and methods of use thereof
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
EP2505209A1 (en) 2006-06-26 2012-10-03 MacroGenics, Inc. Fcgamma-RIIB-specific antibodies and methods of the use thereof
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
CN106349390B (en) 2008-04-02 2019-12-10 宏观基因有限公司 BCR-complex-specific antibodies and methods of use thereof
AU2009231991B2 (en) 2008-04-02 2014-09-25 Macrogenics, Inc. HER2/neu-specific antibodies and methods of using same
PL2486141T3 (en) 2009-10-07 2018-07-31 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
SG10201604336VA (en) 2010-03-04 2016-07-28 Macrogenics Inc Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
CR20180484A (en) 2016-04-15 2019-03-05 Macrogenics Inc NEW B7-H3 UNON MOLECULES, ANTIBODY-DRUG CONJUGATES OF THE SAME AND METHODS OF USE OF THE SAME

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012231A1 (en) * 1991-12-13 1993-06-24 Dow Chemical (Australia) Limited Composite antibodies of human subgroup iv light chain capable of binding to tag-72

Also Published As

Publication number Publication date
WO1999019362A1 (en) 1999-04-22

Similar Documents

Publication Publication Date Title
AU4754397A (en) Bispecific molecules directed to tumor associated glycoprotein-72 and fc receptor
AU2363695A (en) Human tumor necrosis factor receptors
AUPO203996A0 (en) Therapeutic uses
AU5343196A (en) Quinazoline derivative
AU5343496A (en) Quinazoline derivative
AUPO625497A0 (en) Analysis of molecules
AU7378198A (en) Therapeutic ultrasound system
AU7830398A (en) Human tumor necrosis factor receptor tr9
ZA952587B (en) Human tumor necrosis factor receptor
AU1184399A (en) Therapeutic molecules
AU5119296A (en) Magnetotherapy unit
AU6842198A (en) Hair-treatment substance application
AU7607098A (en) New human ribonuclease
AU3668499A (en) Human receptor molecules
AU6035398A (en) Human c5a-like receptor
AU8163598A (en) Hypoxic tent system
AU2579495A (en) Page makeup system
AU6655596A (en) Tent
AUPM375194A0 (en) Cytokine receptor interactive molecules
AU8019494A (en) Human endothelin-bombesin receptor
AUPM885894A0 (en) Therapeutic molecules
AU5506996A (en) Sunbed
AU2134395A (en) Improved construction of umbrella
AUPP263498A0 (en) Novel therapeutic molecules and uses therefor
AUPO926397A0 (en) Novel therapeutic molecules

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase